Mistletoe for cancer? A systematic review of randomised clinical trials

International Journal of Cancer

Volumn 107, Issue 2, 2003, Pages 262-267

  Ernst, Eduard ^a   Schmidt, Katja ^b   Steuer Vogt, Miriam Katharina ^b  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Alternative medicine; Cancer; Mistletoe; Viscum album

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; ISCADOR Q; ISCADOR U; NEY TUMORIN; POLYERGA; RECOMBINANT ALPHA2 INTERFERON; VISCUM ALBUM EXTRACT; VISCUM ALBUM LECTIN; XENOBIOTIC AGENT;

ANTINEOPLASTIC ACTIVITY; BIBLIOGRAPHIC DATABASE; CANCER; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; HUMAN; MEDICAL LITERATURE; METHODOLOGY; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; VALIDATION PROCESS; VISCUM ALBUM;

CLINICAL TRIALS; DATABASES, FACTUAL; HUMANS; MISTLETOE; NEOPLASMS; PHYTOTHERAPY; PLANT PREPARATIONS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE;

EID: 0141857776     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11386     Document Type: Review

References (31)

1. Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 1998;83:777-82.
2. Grothey A, Düppe J, Hasenburg A, Voigtmann R. Use of alternative medicine in oncology patients. Dtsch Med Wochenschr 1998;123:923-9.
3. Haustein KO. Immuntherapeutika und Zytostatika. Berlin: Springer, 1998.
4. Majewski A, Bentele W. Über Zusatzbehandlung beim weiblichen Genitalkarzinom. Zentralbl Gyn 1963;20:696-700.
5. Kiene H. Klinische Studien zur Misteltherapie karzinomatöser Erkrankungen. Therapeutikon 1989;6:347-53.
6. Edler L. Randomisierte klinische Studien zur Misteltherapie bei Krebs: Ergebnisse, Erfahrungen und Perspektiven. In: Scheer R, Becker H, Berg PA. Grundlagen der Misteltherapie. Stuttgart: Hippokrates-Verlag GmbH, 1996, 508-18.
7. Kaegi E. Unconventional therapies for cancer 3 Iscador. CMAJ 1998;158:1157-9.
8. Gabius S, Gabius HJ. Immunmodulierende Misteltherapie durch Lektinstandardisierung: ein zweischneidiges Schwert? Versicherungsmedizin 1999;51:128-36.
9. Willeck K. Studien zur Misteltherapie. Eine aktuelle Übersicht mit Kurzfassungen der wichtigsten Studien 1996-2001. Erfahrungsheilkunde 2002;4:260-3.
10. Kleijnen J, Knipschild P. Mistletoe treatment for cancer: review of controlled trials in humans. Phytomed 1994;1:255-60.
11. Jadad AR, Moore RA, Carrol D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Contr Clin Trials 1996;17:1-12.
12. Douwes FR, Wolfrum DI, Migeod F. Ergebnisse einer prospektiv randomisierten Studie: chemotherapie versus Chemotherapie plus "Biological Response Modifier" bei metastasierendem kolorektalem Karzinom. Dtsch Z Onkol 1986;19:155-64.
13. Dold U, Edler L, Mäurer HC, Müller-Wening D, Sakellariou B, Trendelenburg F, Wagner B. Krebszusatztherapie beim fortgeschrittenen nicht-kleinzelligen Bronchialkarzinom. Stuttgart: Georg Thieme Verlag, 1991.
14. Salzer G, Danmayer E, Wutzlhofer F, Frey S. Adjuvante Iscador-Behandlung operierter nicht kleinzelliger Bronchuskarzinome: ergebnisse einer randomisierten Studie. Dtsch Z Onkol 1991;23:93-8.
15. Lenartz D, Stoffel B, Menzel J, Beuth J. Immunoprotective activity of the galactoside-specific lectin from mistletoe after tumor destructive therapy in glioma patients. Anticancer Res 1996;16:3799-802.
16. Lenartz D, Dott U, Menzel J, Beuth J. Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res 2000;20:2073-6.
17. Heiny BM, Albrecht V. Komplementäre Therapie mit Mistellektin-1-normiertem Extrakt. Med Welt 1997;48:419-23.
18. Kleeberg UR, Bröcker EB, Lejeune F, Chartier C, Egger C, Marsden J, Ruiter D, Suciu S. Adjuvant trial in melanoma patients comparing rIFN-alpha to rIFN-gamma to Iscador to a control group after curative resection of high risk primary (≥3 mm) or regional lymph node metastasis (EORTC 18871). Eur J Cancer 1999;(suppl. 4):S82 (abstract 264).
19. Schafer M, Wetzel D. Ca-ML Studie. Germany: Madaus, internal document dated 08/05/2000. 2002.
20. Grossarth-Maticek R, Kiene H, Baumgartner SM, Ziegler R. Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pairs studies nested within a cohort study. Altern Ther Health Med 2001;7:57-78.
21. Resch KL. Mistletoe and survival time: too much room for bias. FACT 2001;6:189-91.
22. Steuer-Vogt MK, Bonkowsky V, Ambrosch P, Scholz M, Neibata A, Strutz J, Hennig M, Lenarz T, Arnold W. The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer 2001;37:23-31.
23. Goebell PJ, Otto T, Suhr J, Rübben H. Evaluation on an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized, phase II trial. J Urology 2002;168:72-5.
24. Bott V. Anthroposophische Medizin. Haug Verlag; Heidelberg. 1982.
25. Hajto T, Hostanska K, Frei K, Rohrdorf C, Gabius HJ. Increased secretion of tumor necrosis factor α, interleukin-1 and interleukin-6 by human mononuclear cells exposed to galactoside-specific lectin from clinically applied mistletoe extract. Cancer Res 1990;50:3322-6.
26. Elsasser-Beile U, Voss M, Schule R, Wetterauer U. Biological effects of natural and recombinant mistletoe lectin and an aqueous mistletoe extract on human monocytes and lymphocytes in vitro. J Clin Lab Anal 2000;14:255-9.
27. Nikolai G, Friedl P, Werner M, Niggemann B, Zanker KS. Effect of a mistletoe extract (Iscador QuFrF) on viability and migratory behavior of human peripheral CD4+ and CD8+ T lymphocytes in three-dimensional collagen lattices. In Vitro Cell Div Biol Anim 1997;33:710-6.
28. Pae HO, Seo WG, Oh GS, Shin MK, Lee HS, Kim SB, Chung HT. Potentiation of tumor necrosis factor-alpha-induced apoptosis by mistletoe lectin. Immunopharmacol Immunotoxicol 2000;22:697-709.
29. Ernst E. Mistletoe for cancer? Eur J Cancer 2001;37:9-11.
30. Loewe-Mesch A. Die Misteltherapie in der biologischen Tumorbegleitbehandlung. EHK 2002;4:256-8.
31. Steuer-Vogt MK. Bonkowsky V, Scholz M, Arnold W. Plattenepithelkarzinome des Kopf-Hals-Bereichs. Mistellektin-1-normierte Viscumtherapie. Dt Aerztebl 2001;98:A3036-46.